Ocugen, Inc. (OCGN)

Progress In Clinical Trials Overshadows FY2023 Filing Delay


Robert LeBoyerMedia Inquiries
Senior Life Sciences Analyst
April 3, 2024
Report ID: 26637
Get Report
Refer to the full report for the price target, fundamental analysis, and rating.

Equity Research provided by Noble Capital Markets is available at no cost to Registered users of Channelchek.

Already Registered? Click the ‘Get Report’ button to login and view the research report.

Not a Member? Click ‘Join’ or ‘Get Report’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

Ticker
OCGN
Current Price
$1.32
Market Cap
$339.7M
Price Target
Refer to Report
Volume
6.6M
52wk Range
$0.345 - $2.105
Related Research Reports
4/9/2024

Phase 3 IND Clearance Is Good News We’ve Been Waiting For
Phase 3 IND Clearance Is Good News We’ve Been Waiting For (OCGN)
4/3/2024

Progress In Clinical Trials Overshadows FY2023 Filing Delay
Progress In Clinical Trials Overshadows FY2023 Filing Delay (OCGN)
2/22/2024

Ocugen Clinical Showcase Meeting Details OCU400 and Potential Gene Therapy Breakthroughs
Ocugen Clinical Showcase Meeting Details OCU400 and Potential Gene Therapy Breakthroughs (OCGN)
2/12/2024

Raising Price Target to $8 Based On Clinical Progress
Raising Price Target to $8 Based On Clinical Progress (OCGN)

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2024 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.